Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced its participation to the 34th edition of the annual J.P. Morgan Healthcare Conference which will be held from 11 to 15 January 2016 in San Francisco.
The J.P. Morgan Healthcare conference is the largest and most informative healthcare investment conference. This conference attracts a broad range of US-based analysts and institutional investors.
Celyad will meet with US investors and potential partners and share with them its on-going development programs and strategic vision for the future.
Patrick Jeanmart, CFO of Celyad: “2015 was once more rich in events for our company. From the clinical point of view, we completed the European Phase III clinical trial of C-Cure® and started a Phase I clinical trial in our immuno-oncology platform with NKG2D CAR-T cells. From a financial point of view, we did our IPO on NASDAQ which allowed us to raise USD 100,1 million. The J.P. Morgan Healthcare Conference is an excellent opportunity to present Celyad’s potential and strategic vision to new investors in view of increasing the visibility and the awareness of our Company towards large institutional investors.”
